The focus of the Affinity Proteomics Group is to develop, design and apply recombinant antibody microarrays for high-throughput (disease) proteomics, with a particular focus on oncoproteomics and autoimmunity.
1) Technology development: We have adopted a cross-disciplinary approach to develop a state-of-the-art recombinant antibody microarray technology platform(s) capable of handling most sample formats. The platform(s) are contonously being further developed and optimized in order to provide us with cutting edge profiling tools.
2) Applications: We have performed biomarker discovery targeting crude sample formats (e.g. serum, plasma, and urine),with a particular focus on oncoproteomic (e.g. breast cancer, pancreatic cancer, and prostate cancer), autoimmunity (e.g. systemic lupus erythematosus, rheumatoid arthritis, primary sjögren syndrome), as well a other infammatory conditions (e.g. pre-eclampsia).